Is There an Optimal Formulation and Delivery Strategy for Subunit Vaccines?

Pharmaceutical Research

Volumn 33, Issue 9, 2016, Pages 2078-2097

  Bobbala, Sharan ^a   Hook, Sarah ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

hydrogels; immunization; implants; nanoparticles; subunit vaccines

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ARCHAEOSOME; CHITOSAN; CUBOSOME; ISCOM; LIPID; LIPOSOME; POLYGLACTIN; POLYMER; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VIROSOME; ANTIGEN;

BACTERIAL CELL; BACTERIAL GHOST; DRUG DELIVERY SYSTEM; DRUG FORMULATION; EMULSION; HUMAN; HYDROGEL; IMMUNE RESPONSE; IMMUNIZATION; IMPLANT; MICELLE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; VIRUS LIKE AGENT; ANIMAL; ANTIBODY PRODUCTION; IMMUNOLOGY; MEDICINAL CHEMISTRY; PROCEDURES; VACCINATION;

ANIMALS; ANTIBODY FORMATION; ANTIGENS; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; HUMANS; VACCINATION; VACCINES, SUBUNIT;

EID: 84977123358     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-016-1979-0     Document Type: Review

References (240)

1. Lombard M, Pastoret PP, Moulin AM. A brief history of vaccines and vaccination. Rev Sci Tech (Int Off Epizootics). 2007;26(1):29–48.
2. Glew RH. Molecular therapeutics: 21st century medicine by Pamela Greenwell and Michelle McCulley. Biochem Mol Biol Educ. 2008;36(6):444–5.
3. Huang DB, Wu JJ, Tyring SK. A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines. J Infect. 2004;49(3):179–209.
4. Nabel GJ. Designing tomorrow’s vaccines. N Engl J Med. 2013;368(6):551–60.
5. Tandrup Schmidt S, Foged C, Smith Korsholm K, Rades T, Christensen D. Liposome-based adjuvants for subunit vaccines: formulation strategies for subunit antigens and immunostimulators. Pharmaceutics. 2016;8(1):7.
6. Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol. 2009;30(1):23–32.
7. Awate S, Babiuk LA, Mutwiri G. Mechanisms of action of adjuvants. Front Immunol. 2013;4:114.
8. Picker LJ, Hansen SG, Lifson JD. New paradigms for HIV/AIDS vaccine development. Annu Rev Med. 2012;63(1):95–111.
9. Dunachie S, Hill AV, Fletcher HA. Profiling the host response to malaria vaccination and malaria challenge. Vaccine. 2015;33(40):5316–20.
10. Aagaard C, Dietrich J, Doherty M, Andersen P. TB vaccines: current status and future perspectives. Immunol Cell Biol. 2009;87(4):279–86.
11. Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nat Rev Immunol. 2012;12(8):557–69.
12. Emens LA. Cancer vaccines: on the threshold of success. Expert Opin Emerg Drugs. 2008;13(2):295–308.
13. Kallerup RS, Foged C. Classification of vaccines. Subunit vaccine delivery. New York: Springer-Verlag; 2015. p. 15–29.
14. De Gregorio E, Rappuoli R, editors. Novel Immunologic Adjuvants. London: Future Medicine Ltd; 2011.
15. Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol. 2010;10(11):787–96.
16. Neumann S, Young K, Compton B, Anderson R, Painter G, Hook S. Synthetic TRP2 long-peptide and α-galactosylceramide formulated into cationic liposomes elicit CD8+ T-cell responses and prevent tumour progression. Vaccine. 2015;33(43):5838–44.
17. Kamath AT, Mastelic B, Christensen D, Rochat A-F, Agger EM, Pinschewer DD, et al. Synchronization of dendritic cell activation and antigen exposure is required for the induction of Th1/Th17 responses. J Immunol (Baltim, Md: 1950). 2012;188(10):4828–37.
18. Oyewumi MO, Kumar A, Cui Z. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines. 2010;9(9):1095–107.
19. Jones SW, Roberts RA, Robbins GR, Perry JL, Kai MP, Chen K, et al. Nanoparticle clearance is governed by Th1/Th2 immunity and strain background. J Clin Invest. 2013;123(7):3061–73.
20. Shen H, Ackerman AL, Cody V, Giodini A, Hinson ER, Cresswell P, et al. Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology. 2006;117(1):78–88.
21. Sharp FA, Ruane D, Claass B, Creagh E, Harris J, Malyala P, et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci U S A. 2009;106(3):870–5.
22. Harris J, Sharp FA, Lavelle EC. The role of inflammasomes in the immunostimulatory effects of particulate vaccine adjuvants. Eur J Immunol. 2010;40(3):634–8.
23. Neumann S, Burkert K, Kemp R, Rades T, Rod Dunbar P, Hook S. Activation of the NLRP3 inflammasome is not a feature of all particulate vaccine adjuvants. Immunol Cell Biol. 2014;92(6):535–42.
24. Kim M-G, Park JY, Shon Y, Kim G, Shim G, Oh Y-K. Nanotechnology and vaccine development. Asian J Pharm Sci. 2014;9(5):227–35.
25. Mohan T, Verma P, Rao DN. Novel adjuvants & delivery vehicles for vaccines development: a road ahead. Indian J Med Res. 2013;138(5):779–95.
26. Lycke N. Mechanisms of adjuvant action. In: Singh, M, editors. Vaccine adjuvants and delivery systems. New Jersey: John Wiley & Sons, Inc.; 2007. p. 53–79.
27. Vogel FR, Caillet C, Kusters IC, Haensler J. Emulsion-based adjuvants for influenza vaccines. Expert Rev Vaccines. 2009;8(4):483–92.
28. O’Hagan DT, Tsai T, Reed S. Emulsion-based adjuvants for improved influenza vaccines. Influenza vaccines for the future. Basel: Springer; 2011. p. 327–57.
29. Coler RN, Carter D, Friede M, Reed SG. Adjuvants for malaria vaccines. Parasite Immunol. 2009;31(9):520–8.
30. Garçon N, Leroux-Roels G, Cheng W-F. Vaccine adjuvants. Perspect Vaccinology. 2011;1(1):89–113.
31. Zeng BJ, Chuan YP, O’Sullivan B, Caminschi I, Lahoud MH, Thomas R, et al. Receptor-specific delivery of protein antigen to dendritic cells by a nanoemulsion formed using top-down non-covalent click self-assembly. Small. 2013;9(22):3736–42.
32. De Gregorio E, Tritto E, Rappuoli R. Alum adjuvanticity: unraveling a century old mystery. Eur J Immunol. 2008;38(8):2068–71.
33. Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol. 2004;82(5):488–96.
34. Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol. 2009;9(4):287–93.
35. Franchi L, Núñez G. The NLRP3 inflammasome is critical for alum-mediated IL-1β secretion but dispensable for adjuvant activity. Eur J Immunol. 2008;38(8):2085–9.
36. Kool M, Fierens K, Lambrecht BN. Alum adjuvant: some of the tricks of the oldest adjuvant. J Med Microbiol. 2012;61(Pt 7):927–34.
37. Myschik J, Rades T, Hook S. Advances in lipid-based subunit vaccine formulations. Curr Immunol Rev. 2009;5(1):42–8.
38. Henriksen-Lacey M, Korsholm KS, Andersen P, Perrie Y, Christensen D. Liposomal vaccine delivery systems. Expert Opin Drug Deliv. 2011;8(4):505–19.
39. Godsey ME, Suryaprakash S, Leong KW. Materials innovation for co-delivery of diverse therapeutic cargos. RSC Adv. 2013;3(47):24794–811.
40. Gordon S, Young K, Wilson R, Rizwan S, Kemp R, Rades T, et al. Chitosan hydrogels containing liposomes and cubosomes as particulate sustained release vaccine delivery systems. J Liposome Res. 2012;22(3):193–204.
41. Vangala A, Kirby D, Rosenkrands I, Agger EM, Andersen P, Perrie Y. A comparative study of cationic liposome and niosome-based adjuvant systems for protein subunit vaccines: characterisation, environmental scanning electron microscopy and immunisation studies in mice. J Pharm Pharmacol. 2006;58(6):787–99.
42. Ducat E, Brion M, Lecomte F, Evrard B, Piel G. The experimental design as practical approach to develop and optimize a formulation of peptide-loaded liposomes. AAPS PharmSciTech. 2010;11(2):966–75.
43. Fritze A, Hens F, Kimpfler A, Schubert R, Peschka-Süss R. Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient. Biochim Biophys Acta Biomembr. 2006;1758(10):1633–40.
44. Grit M, Crommelin DJ. Chemical stability of liposomes: implications for their physical stability. Chem Phys Lipids. 1993;64(1–3):3–18.
45. Bitounis D, Fanciullino R, Iliadis A, Ciccolini J. Optimizing druggability through liposomal formulations: new approaches to an old concept. ISRN Pharmaceutics. 2012;2012.
46. Bozzuto G, Molinari A. Liposomes as nanomedical devices. Int J Nanomedicine. 2015;10:975–99.
47. Schwendener RA. Liposomes as vaccine delivery systems: a review of the recent advances. Ther Adv Vaccin. 2014;2(6):159–82.
48. The R, Partnership SCT. Efficacy and safety of the RTS, S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med. 2014;11(7):e1001685.
49. van Dissel JT, Joosten SA, Hoff ST, Soonawala D, Prins C, Hokey DA, et al. A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human. Vaccine. 2014;32(52):7098–107.
50. Fan Y, Sahdev P, Ochyl LJ, Akerberg J, Moon JJ. Cationic liposome–hyaluronic acid hybrid nanoparticles for intranasal vaccination with subunit antigens. J Control Release. 2015;208:121–9.
51. Varypataki EM, van der Maaden K, Bouwstra J, Ossendorp F, Jiskoot W. Cationic liposomes loaded with a synthetic long peptide and Poly(I:C): a defined adjuvanted vaccine for induction of antigen-specific T cell cytotoxicity. AAPS J. 2015;17(1):216–26.
52. Sahdev P, Ochyl L, Moon J. Biomaterials for nanoparticle vaccine delivery systems. Pharm Res. 2014;31(10):2563–82.
53. Watarai S, Iwase T, Tajima T, Yuba E, Kono K. Efficiency of pH-sensitive fusogenic polymer-modified liposomes as a vaccine carrier. Sci World J. 2013;2013:7.
54. Watarai S, Iwase T, Tajima T, Yuba E, Kono K, Sekiya Y. Application of pH-sensitive fusogenic polymer-modified liposomes for development of mucosal vaccines. Vet Immunol Immunopathol. 2014;158(1–2):62–72.
55. Nielsen HM, Hübschmann HB, Rades T. ISCOMs as a vaccine delivery system. Subunit vaccine delivery: Springer; 2015. p. 141-58.
56. Morein B, Hu K-F, Abusugra I. Current status and potential application of ISCOMs in veterinary medicine. Adv Drug Deliv Rev. 2004;56(10):1367–82.
57. Sanders MT, Brown LE, Deliyannis G, Pearse MJ. ISCOM-based vaccines: the second decade. Immunol Cell Biol. 2005;83(2):119–28.
58. Robson NC, Donachie AM, Mowat AM. Simultaneous presentation and cross‐presentation of immune‐stimulating complex‐associated cognate antigen by antigen‐specific B cells. Eur J Immunol. 2008;38(5):1238–46.
59. Schnurr M, Orban M, Robson NC, Shin A, Braley H, Airey D, et al. ISCOMATRIX adjuvant induces efficient cross-presentation of tumor antigen by dendritic cells via rapid cytosolic antigen delivery and processing via tripeptidyl peptidase II. J Immunol (Baltim, Md: 1950). 2009;18(3):1253–9.
60. Paepenmüller T, Müller-Goymann CC. Influence of Quil A on liposomal membranes. Int J Pharm. 2014;475(1–2):138–46.
61. Ennis FA, Cruz J, Jameson J, Klein M, Burt D, Thipphawong J. Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS). Virology. 1999;259(2):256–61.
62. Rimmelzwaan GF, Nieuwkoop N, Brandenburg A, Sutter G, Beyer WE, Maher D, et al. A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. Vaccine. 2000;19(9–10):1180–7.
63. McBurney WT, Lendemans DG, Myschik J, Hennessy T, Rades T, Hook S. In vivo activity of cationic immune stimulating complexes (PLUSCOMs). Vaccine. 2008;26(35):4549–56.
64. Lendemans DG, Myschik J, Hook S, Rades T. Cationic cage-like complexes formed by DC-cholesterol, Quil-A, and phospholipid. J Pharm Sci. 2005;94(8):1794–807.
65. Camussone CM, Veaute CM, Pujato N, Morein B, Marcipar IS, Calvinho LF. Immune response of heifers against a Staphylococcus aureus CP5 whole cell and lysate vaccine formulated with ISCOM Matrix adjuvant. Res Vet Sci. 2014;96(1):86–94.
66. Saroja CH, Lakshmi PK, Bhaskaran S. Recent trends in vaccine delivery systems: a review. Int J Pharm Investig. 2011;1(2):64–74.
67. Lynch ML, Ofori-Boateng A, Hippe A, Kochvar K, Spicer PT. Enhanced loading of water-soluble actives into bicontinuous cubic phase liquid crystals using cationic surfactants. J Colloid Interface Sci. 2003;260(2):404–13.
68. Spicer PT, Hayden KL, Lynch ML, Ofori-Boateng A, Burns JL. Novel process for producing cubic liquid crystalline nanoparticles (Cubosomes). Langmuir. 2001;17(19):5748–56.
69. Chen Y, Ma P, Gui S. Cubic and hexagonal liquid crystals as drug delivery systems. BioMed Res Int. 2014;2014:12.
70. Meli V, Caltagirone C, Falchi AM, Hyde ST, Lippolis V, Monduzzi M, et al. Docetaxel-loaded fluorescent liquid-crystalline nanoparticles for cancer theranostics. Langmuir. 2015;31(35):9566–75.
71. Patrick TS. Cubosomes: bicontinuous liquid crystalline nanoparticles. Dekker Encyclopedia of Nanoscience and Nanotechnology, Second Edition: Taylor & Francis; 2009. p. 1018–28.
72. Spicer PT. Bicontinuous Liquid Crystalline Nanoparticles, Second Edition. Dekker Encyclopedia of Nanoscience and Nanotechnology. London: Taylor & Francis; 2009. p. 1018–28.
73. Rizwan SB, Boyd BJ. Cubosomes: structure, preparation and use as an antigen delivery system. Subunit Vaccine Delivery: Springer; 2015. p. 125–40.
74. Rizwan SB, McBurney WT, Young K, Hanley T, Boyd BJ, Rades T, et al. Cubosomes containing the adjuvants imiquimod and monophosphoryl lipid A stimulate robust cellular and humoral immune responses. J Control Release. 2013;165(1):16–21.
75. Moser C, Amacker M, Kammer AR, Rasi S, Westerfeld N, Zurbriggen R. Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations. Expert Rev Vaccines. 2007;6(5):711–21.
76. Peduzzi E, Westerfeld N, Zurbriggen R, Pluschke G, Daubenberger CA. Contribution of influenza immunity and virosomal-formulated synthetic peptide to cellular immune responses in a phase I subunit malaria vaccine trial. Clin Immunol. 2008;127(2):188–97.
77. Bungener L, Huckriede A, de Mare A, de Vries-Idema J, Wilschut J, Daemen T. Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity. Vaccine. 2005;23(10):1232–41.
78. Herzog C, Hartmann K, Künzi V, Kürsteiner O, Mischler R, Lazar H, et al. Eleven years of Inflexal® V—a virosomal adjuvanted influenza vaccine. Vaccine. 2009;27(33):4381–7.
79. Moser C, Müller M, Kaeser MD, Weydemann U, Amacker M. Influenza virosomes as vaccine adjuvant and carrier system. Expert Rev Vaccines. 2013;12(7):779–91.
80. Liu H, de Vries-Idema J, ter Veer W, Wilschut J, Huckriede A. Influenza virosomes supplemented with GPI-0100 adjuvant: a potent vaccine formulation for antigen dose sparing. Med Microbiol Immunol. 2014;203(1):47–55.
81. Kamphuis T, Stegmann T, Meijerhof T, Wilschut J, de Haan A. A virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A provides protection against viral challenge without priming for enhanced disease in cotton rats. Influenza Other Respir Viruses. 2013;7(6):1227–36.
82. Jain S, Caforio A, Driessen AJM. Biosynthesis of archaeal membrane ether lipids. Front Microbiol. 2014;5:641.
83. Benvegnu T, Lemiègre L, Cammas-Marion S. New generation of liposomes called archaeosomes based on natural or synthetic archaeal lipids as innovative formulations for drug delivery. Recent Pat Drug Deliv Formulation. 2009;3(3):206–20.
84. Sprott GD, Sad S, Fleming LP, DiCaire CJ, Patel GB, Krishnan L. Archaeosomes varying in lipid composition differ in receptor-mediated endocytosis and differentially adjuvant immune responses to entrapped antigen. Archaea. 2003;1(3):151–64.
85. Patel GB, Zhou H, KuoLee R, Chen W. Archaeosomes as adjuvants for combination vaccines. J Liposome Res. 2004;14(3–4):191–202.
86. Patel GB, Chen W. Archaeal lipid mucosal vaccine adjuvant and delivery system. Expert Rev Vaccines. 2010;9(4):431–40.
87. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Preat V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release: Off J Control Release Soc. 2012;161(2):505–22.
88. Cheung RCF, Ng TB, Wong JH, Chan WY. Chitosan: an update on potential biomedical and pharmaceutical applications. Mar Drugs. 2015;13(8):5156–86.
89. Arca HC, Gunbeyaz M, Senel S. Chitosan-based systems for the delivery of vaccine antigens. Expert Rev Vaccines. 2009;8(7):937–53.
90. Amidi M, Mastrobattista E, Jiskoot W, Hennink WE. Chitosan-based delivery systems for protein therapeutics and antigens. Adv Drug Deliv Rev. 2010;62(1):59–82.
91. Domard A, Gey C, Rinaudo M, Terrassin C. 13C and 1H n.m.r. spectroscopy of chitosan and N-trimethyl chloride derivatives. Int J Biol Macromol. 1987;9(4):233–7.
92. Wang JJ, Zeng ZW, Xiao RZ, Xie T, Zhou GL, Zhan XR, et al. Recent advances of chitosan nanoparticles as drug carriers. Int J Nanomedicine. 2011;6:765–74.
93. Nagamoto T, Hattori Y, Takayama K, Maitani Y. Novel chitosan particles and chitosan-coated emulsions inducing immune response via intranasal vaccine delivery. Pharm Res. 2004;21(4):671–4.
94. Porporatto C, Bianco ID, Correa SG. Local and systemic activity of the polysaccharide chitosan at lymphoid tissues after oral administration. J Leukoc Biol. 2005;78(1):62–9.
95. Gordon S, Saupe A, McBurney W, Rades T, Hook S. Comparison of chitosan nanoparticles and chitosan hydrogels for vaccine delivery. J Pharm Pharmacol. 2008;60(12):1591–600.
96. Pawar D, Jaganathan KS. Mucoadhesive glycol chitosan nanoparticles for intranasal delivery of hepatitis B vaccine: enhancement of mucosal and systemic immune response. Drug Deliv. 2014:1–11.
97. Makadia HK, Siegel SJ. Poly Lactic-co-Glycolic Acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers. 2011;3(3):1377–97.
98. Bhaskar S, Pollock KM, Yoshida M, Lahann J. Towards designer microparticles: simultaneous control of anisotropy, shape, and size. Small. 2010;6(3):404–11.
99. Milacic V, Bailey BA, O’Hagan D, Schwendeman SP. Injectable PLGA systems for delivery of vaccine antigens. Long acting injections and implants: Springer; 2012. p. 429–58.
100. Salvador A, Igartua M, Hernández RM, Pedraz JL. An overview on the field of micro- and nanotechnologies for synthetic peptide-based vaccines. J Drug Deliv. 2011;2011:181646.
101. Silva AL, Soema PC, Slütter B, Ossendorp F, Jiskoot W. PLGA particulate delivery systems for subunit vaccines: linking particle properties to immunogenicity. Hum Vaccines Immunother. 2016:1–14.
102. Allahyari M, Mohit E. Peptide/protein vaccine delivery system based on PLGA particles. Hum Vaccin Immunother. 2016;12(3):806–28.
103. Krishnamachari Y, Geary SM, Lemke CD, Salem AK. Nanoparticle delivery systems in cancer vaccines. Pharm Res. 2011;28(2):215–36.
104. Torchilin VP. Multifunctional nanocarriers. Adv Drug Deliv Rev. 2006;58(14):1532–55.
105. Irvine DJ, Hanson MC, Rakhra K, Tokatlian T. Synthetic nanoparticles for vaccines and Immunotherapy. Chem Rev. 2015;115(19):11109–46.
106. Kasturi SP, Skountzou I, Albrecht RA, Koutsonanos D, Hua T, Nakaya HI, et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature. 2011;470(7335):543–7.
107. San Roman B, Irache JM, Gomez S, Tsapis N, Gamazo C, Espuelas MS. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology. Eur J Pharm Biopharm: Off J Arbeitsgemeinschaft Pharm Verfahrenstechnik eV. 2008;70(1):98–108.
108. Shi S, Hickey AJ. PLGA microparticles in respirable sizes enhance an in vitro T cell response to recombinant Mycobacterium tuberculosis antigen TB10.4-Ag85B. Pharm Res. 2010;27(2):350–60.
109. Carcaboso AM, Hernandez RM, Igartua M, Rosas JE, Patarroyo ME, Pedraz JL. Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles. Vaccine. 2004;22(11–12):1423–32.
110. Zhang Z, Tongchusak S, Mizukami Y, Kang YJ, Ioji T, Touma M, et al. Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery. Biomaterials. 2011;32(14):3666–78.
111. Demento SL, Cui W, Criscione JM, Stern E, Tulipan J, Kaech SM, et al. Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype. Biomaterials. 2012;33(19):4957–64.
112. Rosalia RA, Cruz LJ, van Duikeren S, Tromp AT, Silva AL, Jiskoot W, et al. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses. Biomaterials. 2015;40:88–97.
113. Scott EA, Stano A, Gillard M, Maio-Liu AC, Swartz MA, Hubbell JA. Dendritic cell activation and T cell priming with adjuvant- and antigen-loaded oxidation-sensitive polymersomes. Biomaterials. 2012;33(26):6211–9.
114. Stano A, Scott EA, Dane KY, Swartz MA, Hubbell JA. Tunable T cell immunity towards a protein antigen using polymersomes vs. solid-core nanoparticles. Biomaterials. 2013;34(17):4339–46.
115. Trimaille T, Verrier B. Micelle-based adjuvants for subunit vaccine delivery. Vaccines. 2015;3(4):803–13.
116. Luo Z, Shi S, Jin L, Xu L, Yu J, Chen H, et al. Cationic micelle based vaccine induced potent humoral immune response through enhancing antigen uptake and formation of germinal center. Colloids Surf B: Biointerfaces. 2015;135:556–64.
117. Jain AK, Goyal AK, Gupta PN, Khatri K, Mishra N, Mehta A, et al. Synthesis, characterization and evaluation of novel triblock copolymer based nanoparticles for vaccine delivery against hepatitis B. J Control Release. 2009;136(2):161–9.
118. Coumes F, Huang C-Y, Huang C-H, Coudane J, Domurado D, Li S, et al. Design and development of immunomodulatory antigen delivery systems based on peptide/PEG–PLA conjugate for tuning immunity. Biomacromolecules. 2015;16(11):3666–73.
119. Jiménez-Sánchez G, Pavot V, Chane-Haong C, Handké N, Terrat C, Gigmes D, et al. Preparation and in vitro evaluation of imiquimod loaded polylactide-based micelles as potential vaccine adjuvants. Pharm Res. 2015;32(1):311–20.
120. Wilson J, Postma A, Keller S, Convertine A, Moad G, Rizzardo E, et al. Enhancement of MHC-I antigen presentation via architectural control of pH-responsive, endosomolytic polymer nanoparticles. AAPS J. 2015;17(2):358–69.
121. Liu H, Moynihan KD, Zheng Y, Szeto GL, Li AV, Huang B, et al. Structure-based programming of lymph-node targeting in molecular vaccines. Nature. 2014;507(7493):519–22.
122. Trent A, Ulery BD, Black MJ, Barrett JC, Liang S, Kostenko Y, et al. Peptide amphiphile micelles self-adjuvant group a streptococcal vaccination. AAPS J. 2015;17(2):380–8.
123. Kushnir N, Streatfield SJ, Yusibov V. Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine. 2012;31(1):58–83.
124. Lua LHL, Connors NK, Sainsbury F, Chuan YP, Wibowo N, Middelberg APJ. Bioengineering virus-like particles as vaccines. Biotechnol Bioeng. 2014;111(3):425–40.
125. Chackerian B, Rangel M, Hunter Z, Peabody DS. Virus and virus-like particle-based immunogens for Alzheimer’s disease induce antibody responses against amyloid-β without concomitant T cell responses. Vaccine. 2006;24(37–39):6321–31.
126. Kazaks A, Balmaks R, Voronkova T, Ose V, Pumpens P. Melanoma vaccine candidates from chimeric hepatitis B core virus-like particles carrying a tumor-associated MAGE-3 epitope. Biotechnol J. 2008;3(11):1429–36.
127. Keller SA, Bauer M, Manolova V, Muntwiler S, Saudan P, Bachmann MF. Cutting edge: limited specialization of dendritic cell subsets for MHC class II-associated presentation of viral particles. J Immunol. 2010;184(1):26–9.
128. Roldão A, Mellado MCM, Castilho LR, Carrondo MJT, Alves PM. Virus-like particles in vaccine development. Expert Rev Vaccines. 2010;9(10):1149–76.
129. Al-Barwani F, Donaldson B, Pelham SJ, Young SL, Ward VK. Antigen delivery by virus-like particles for immunotherapeutic vaccination. Ther Deliv. 2014;5(11):1223–40.
130. Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30(Supplement 5):F123-F38.
131. Thompson CM, Petiot E, Mullick A, Aucoin MG, Henry O, Kamen AA. Critical assessment of influenza VLP production in Sf9 and HEK293 expression systems. BMC Biotechnol. 2015;15(1):31.
132. Muhammad A, Champeimont J, Mayr UB, Lubitz W, Kudela P. Bacterial ghosts as carriers of protein subunit and DNA-encoded antigens for vaccine applications. Expert Rev Vaccines. 2012;11(1):97–116.
133. Langemann T, Koller VJ, Muhammad A, Kudela P, Mayr UB, Lubitz W. The bacterial ghost platform system. Bioengineered Bugs. 2010;1(5):326–36.
134. Ramey K, Eko FO, Thompson WE, Armah H, Igietseme JU, Stiles JK. Immunolocalization and challenge studies using a recombinant vibrio cholerae ghost expressing trypanosoma brucei Ca2+ ATPase (TBCA2) antigen. AmJTrop Med Hyg. 2009;81(3):407–15.
135. Jechlinger W, Haller C, Resch S, Hofmann A, Szostak MP, Lubitz W. Comparative immunogenicity of the Hepatitis B virus core 149 antigen displayed on the inner and outer membrane of bacterial ghosts. Vaccine. 2005;23(27):3609–17.
136. Langemann T, Koller VJ, Muhammad A, Kudela P, Mayr UB, Lubitz W. The bacterial ghost platform system: production and applications. Bioengineered Bugs. 2010;1(5):326–36.
137. Riedmann EM, Kyd JM, Cripps AW, Lubitz W. Bacterial ghosts as adjuvant particles. Expert Rev Vaccines. 2007;6(2):241–53.
138. Pan Q, Pais R, Ohandjo A, He C, He Q, Omosun Y, et al. Comparative evaluation of the protective efficacy of two formulations of a recombinant Chlamydia abortus subunit candidate vaccine in a mouse model. Vaccine. 2015;33(15):1865–72.
139. Chen J, Li N, She F. Helicobacter pylori outer inflammatory protein DNA vaccine-loaded bacterial ghost enhances immune protective efficacy in C57BL/6 mice. Vaccine. 2014;32(46):6054–60.
140. Jawale CV, Chaudhari AA, Lee JH. Generation of a safety enhanced Salmonella Gallinarum ghost using antibiotic resistance free plasmid and its potential as an effective inactivated vaccine candidate against fowl typhoid. Vaccine. 2014;32(9):1093–9.
141. McHugh KJ, Guarecuco R, Langer R, Jaklenec A. Single-injection vaccines: progress, challenges, and opportunities. J Control Release. 2015;219:596–609.
142. El-Sherbiny IM, Yacoub MH. Hydrogel scaffolds for tissue engineering: progress and challenges. Global Cardiol Sci Pract. 2013:38.
143. Kashyap N, Kumar N, Kumar MN. Hydrogels for pharmaceutical and biomedical applications. Crit Rev Ther Drug Carrier Syst. 2005;22(2):107–49.
144. Nguyen MK, Lee DS. Injectable biodegradable hydrogels. Macromol Biosci. 2010;10(6):563–79.
145. Dumortier G, Grossiord JL, Agnely F, Chaumeil JC. A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm Res. 2006;23(12):2709–28.
146. Klouda L, Mikos AG. Thermoresponsive hydrogels in biomedical applications. Eur J Pharm Biopharm: Off J Arbeitsgemeinschaft Pharm Verfahrenstechnik eV. 2008;68(1):34–45.
147. Kojarunchitt T, Baldursdottir S, Dong Y-D, Boyd BJ, Rades T, Hook S. Modified thermoresponsive Poloxamer 407 and chitosan sol–gels as potential sustained-release vaccine delivery systems. Eur J Pharm Biopharm. 2015;89:74–81.
148. Wu Q, Gong C, Shi S, Wang Y, Huang M, Yang L, et al. Mannan loaded biodegradable and injectable thermosensitive PCL-PEG-PCL hydrogel for vaccine delivery. Soft Mater. 2012;10(4):472–86.
149. Bobbala S, Tamboli V, McDowell A, Mitra A, Hook S. Novel injectable pentablock copolymer based thermoresponsive hydrogels for sustained release vaccines. AAPS J. 2016;18(1):261–9.
150. Gordon S, Teichmann E, Young K, Finnie K, Rades T, Hook S. In vitro and in vivo investigation of thermosensitive chitosan hydrogels containing silica nanoparticles for vaccine delivery. Eur J Pharm Sci. 2010;41(2):360–8.
151. Neimert-Andersson T, Hällgren A-C, Andersson M, Langebäck J, Zettergren L, Nilsen-Nygaard J, et al. Improved immune responses in mice using the novel chitosan adjuvant ViscoGel, with a Haemophilus influenzae type b glycoconjugate vaccine. Vaccine. 2011;29(48):8965–73.
152. Neimert-Andersson T, Binnmyr J, Enoksson M, Langebäck J, Zettergren L, Hällgren A-C, et al. Evaluation of safety and efficacy as an adjuvant for the chitosan-based vaccine delivery vehicle ViscoGel in a single-blind randomised Phase I/IIa clinical trial. Vaccine. 2014;32(45):5967–74.
153. Gübeli RJ, Schöneweis K, Huzly D, Ehrbar M, Hamri GC-E, El-Baba MD, et al. Pharmacologically triggered hydrogel for scheduling hepatitis B vaccine administration. Sci Rep. 2013;3:2610.
154. Kemp JM, Kajihara M, Nagahara S, Sano A, Brandon M, Lofthouse S. Continuous antigen delivery from controlled release implants induces significant and anamnestic immune responses. Vaccine. 2002;20(7–8):1089–98.
155. Even MP, Bobbala S, Kooi KL, Hook S, Winter G, Engert J. Impact of implant composition of twin-screw extruded lipid implants on the release behavior. Int J Pharm. 2015;493(1–2):102–10.
156. Engert J. Implants as sustained release delivery devices for vaccine antigens. Subunit Vaccine Delivery: Springer; 2015. p. 221-41.
157. Lofthouse S, Nagahara S, Sedgmen B, Barcham G, Brandon M, Sano A. The application of biodegradable collagen minipellets as vaccine delivery vehicles in mice and sheep. Vaccine. 2001;19(30):4318–27.
158. Appel B, Maschke A, Weiser B, Sarhan H, Englert C, Angele P, et al. Lipidic implants for controlled release of bioactive insulin: effects on cartilage engineered in vitro. Int J Pharm. 2006;314(2):170–8.
159. Myschik J, McBurney WT, Hennessy T, Phipps-Green A, Rades T, Hook S. Immunostimulatory biodegradable implants containing the adjuvant Quil-A--part II: in vivo evaluation. J Drug Target. 2008;16(3):224–32.
160. Even M-P, Young K, Winter G, Hook S, Engert J. In vivo investigation of twin-screw extruded lipid implants for vaccine delivery. Eur J Pharm Biopharm. 2014;87(2):338–46.
161. Shaji J, Patole V. Protein and peptide drug delivery: oral approaches. Indian J Pharm Sci. 2008;70(3):269–77.
162. Johansen P, Kündig TM. Parenteral vaccine administration: tried and true. Subunit Vaccine Delivery: Springer; 2015. p. 261–86.
163. Zuckerman JN. The importance of injecting vaccines into muscle: different patients need different needle sizes. BMJ: Bri Med J. 2000;321(7271):1237–8.
164. Zehrung D, Jarrahian C, Wales A. Intradermal delivery for vaccine dose sparing: overview of current issues. Vaccine. 2013;31(34):3392–5.
165. Herzog C. Influence of parenteral administration routes and additional factors on vaccine safety and immunogenicity: a review of recent literature. Expert Rev Vaccines. 2014;13(3):399–415.
166. Malm M, Tamminen K, Vesikari T, Blazevic V. Comparison of intramuscular, intranasal and combined administration of norovirus virus-like particle subunit vaccine candidate for induction of protective immune responses in mice. J Clin Cell Immunol. 2015;6(284):2.
167. Pflicke H, Sixt M. Preformed portals facilitate dendritic cell entry into afferent lymphatic vessels. J Exp Med. 2009;206(13):2925–35.
168. Bobbala S, Tamboli V, McDowell A, Mitra A, Hook S. Novel injectable pentablock copolymer based thermoresponsive hydrogels for sustained release vaccines. AAPS J. 2015:1–9.
169. Myschik J, Eberhardt F, Rades T, Hook S. Immunostimulatory biodegradable implants containing the adjuvant quil-a. Part I: physicochemical characterisation. J Drug Target. 2008;16(3):213–23.
170. Tsang P, Gorse GJ, Strout CB, Sperling M, Greenberg DP, Ozol-Godfrey A, et al. Immunogenicity and safety of fluzone® intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial. Vaccine. 2014;32(21):2507–17.
171. Gorse GJ, Falsey AR, Johnson CM, Morrison D, Fried DL, Ervin JE, et al. Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18–64 years of age. Vaccine. 2013;31(50):6034–40.
172. Coleman BL, McNeil SA, Langley JM, Halperin SA, McGeer AJ. Differences in efficiency, satisfaction and adverse events between self-administered intradermal and nurse-administered intramuscular influenza vaccines in hospital workers. Vaccine. 2015;33(48):6635–40.
173. Anassi E, Ndefo UA. Sipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer. Pharm Ther. 2011;36(4):197–202.
174. Richie TL, Billingsley PF, Sim BKL, James ER, Chakravarty S, Epstein JE, et al. Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines. Vaccine. 2015;33(52):7452–61.
175. S-i F, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFN-[gamma]-producing NKT response induced with [alpha]-galactosylceramide-loaded DCs. Nat Immunol. 2002;3(9):867–74.
176. Thapa P, Zhang G, Xia C, Gelbard A, Overwijk WW, Liu C, et al. Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy. Vaccine. 2009;27(25–26):3484–8.
177. Johansen P, ndig TM. Intralymphatic Immunotherapy and Vaccination in Mice. J Vis Exp. 2014(84):e51031.
178. Senti G, Kündig T. Intralymphatic immunotherapy. World Allergy Organ J. 2015;8(1):1–5.
179. Jewell CM, López SCB, Irvine DJ. In situ engineering of the lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particles. Proc Natl Acad Sci. 2011;108(38):15745–50.
180. Andorko JI, Tostanoski LH, Solano E, Mukhamedova M, Jewell CM. Intra-lymph node injection of biodegradable polymer particles. J Vis Exp. 2014;83:50984.
181. Slütter B, Bal SM, Ding Z, Jiskoot W, Bouwstra JA. Adjuvant effect of cationic liposomes and CpG depends on administration route. Journal of controlled release: official journal of the Controlled Release Society. 2011;154(2):123–30.
182. Patravale V, Prabhu P. Potential of nanocarriers in antigen delivery: the path to successful vaccine delivery. Nanocarriers. 2014;1(1):10–45.
183. Luongo D, D’Arienzo R, Bergamo P, Maurano F, Rossi M. Immunomodulation of Gut-associated lymphoid tissue: current perspectives. Int Rev Immunol. 2009;28(6):446–64.
184. Lycke N. Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol. 2012;12(8):592–605.
185. Davitt CJ, Lavelle EC. Delivery strategies to enhance oral vaccination against enteric infections. Adv Drug Deliv Rev. 2015;91:52–69.
186. Wang S, Liu H, Zhang X, Qian F. Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies. Protein Cell. 2015;6(7):480–503.
187. Lai SK, Wang Y-Y, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev. 2009;61(2):158–71.
188. Liau JJ, Hook S, Prestidge CA, Barnes TJ. A lipid based multi-compartmental system: liposomes-in-double emulsion for oral vaccine delivery. Eur J Pharm Biopharm. 2015;97(Part A):15–21.
189. Chan HT, Daniell H. Plant‐made oral vaccines against human infectious diseases—are we there yet? Plant Biotechnol J. 2015;13(8):1056–70.
190. Hayden CA, Fischer ME, Andrews BL, Chilton HC, Turner DD, Walker JH, et al. Oral delivery of wafers made from HBsAg-expressing maize germ induces long-term immunological systemic and mucosal responses. Vaccine. 2015;33(25):2881–6.
191. Lugton IW. Mucosa-associated lymphoid tissues as sites for uptake, carriage and excretion of tubercle bacilli and other pathogenic mycobacteria. Immunol Cell Biol. 1999;77(4):364–72.
192. Amorij J-P, Kersten GFA, Saluja V, Tonnis WF, Hinrichs WLJ, Slütter B, et al. Towards tailored vaccine delivery: needs, challenges and perspectives. J Control Release. 2012;161(2):363–76.
193. Chadwick S, Kriegel C, Amiji M. Nanotechnology solutions for mucosal immunization. Adv Drug Deliv Rev. 2010;62(4–5):394–407.
194. Li H-S, Singh B, Park T-E, Hong Z-S, Kang S-K, Cho C-S, et al. Mannan-decorated thiolated Eudragit microspheres for targeting antigen presenting cells via nasal vaccination. Eur J Pharm Sci. 2015;80:16–25.
195. Scherließ R. Nasal administration of vaccines. In: Foged C, Rades T, Perrie Y, Hook S, editors. Subunit vaccine delivery. Advances in delivery science and technology. New York: Springer; 2015. p. 287–306.
196. Scherließ R, Mönckedieck M, Young K, Trows S, Buske S, Hook S. First in vivo evaluation of particulate nasal dry powder vaccine formulations containing ovalbumin in mice. Int J Pharm. 2015;479(2):408–15.
197. Djupesland PG. Nasal drug delivery devices: characteristics and performance in a clinical perspective—a review. Drug Deliv Transl Res. 2013;3(1):42–62.
198. Holt PG, Oliver J, Bilyk N, McMenamin C, McMenamin PG, Kraal G, et al. Downregulation of the antigen presenting cell function(s) of pulmonary dendritic cells in vivo by resident alveolar macrophages. J Exp Med. 1993;177(2):397–407.
199. Moyron-Quiroz JE, Rangel-Moreno J, Kusser K, Hartson L, Sprague F, Goodrich S, et al. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nat Med. 2004;10(9):927–34.
200. Tonnis WF, Lexmond AJ, Frijlink HW, de Boer AH, Hinrichs WLJ. Devices and formulations for pulmonary vaccination. Expert Opin Drug Deliv. 2013;10(10):1383–97.
201. Tonnis W, Huckriede AW, Hinrichs WJ, Frijlink H. Pulmonary administration of subunit vaccines. In: Foged C, Rades T, Perrie Y, Hook S, editors. Subunit vaccine delivery. Advances in delivery science and technology. New York: Springer; 2015. p. 307–29.
202. Kuzmov A, Minko T. Nanotechnology approaches for inhalation treatment of lung diseases. J Control Release. 2015;219:500–18.
203. Jia Y, Krishnan L, Omri A. Nasal and pulmonary vaccine delivery using particulate carriers. Expert Opin Drug Deliv. 2015;12(6):993–1008.
204. Fromen CA, Robbins GR, Shen TW, Kai MP, Ting JPY, DeSimone JM. Controlled analysis of nanoparticle charge on mucosal and systemic antibody responses following pulmonary immunization. Proc Natl Acad Sci. 2015;112(2):488–93.
205. Waldrep JC, Dhand R. Advanced nebulizer designs employing vibrating mesh/aperture plate technologies for aerosol generation. Curr Drug Deliv. 2008;5(2):114–9.
206. Muttil P, Prego C, Garcia-Contreras L, Pulliam B, Fallon J, Wang C, et al. Immunization of guinea pigs with novel hepatitis B antigen as nanoparticle aggregate powders administered by the pulmonary route. AAPS J. 2010;12(3):330–7.
207. Amidi M, Pellikaan HC, Hirschberg H, de Boer AH, Crommelin DJA, Hennink WE, et al. Diphtheria toxoid-containing microparticulate powder formulations for pulmonary vaccination: preparation, characterization and evaluation in guinea pigs. Vaccine. 2007;25(37–38):6818–29.
208. Amorij JP, Saluja V, Petersen AH, Hinrichs WLJ, Huckriede A, Frijlink HW. Pulmonary delivery of an inulin-stabilized influenza subunit vaccine prepared by spray-freeze drying induces systemic, mucosal humoral as well as cell-mediated immune responses in BALB/c mice. Vaccine. 2007;25(52):8707–17.
209. Lu D, Garcia-Contreras L, Muttil P, Padilla D, Xu D, Liu J, et al. Pulmonary immunization using antigen 85-B polymeric microparticles to boost tuberculosis immunity. AAPS J. 2010;12(3):338–47.
210. Pavot V, Rochereau N, Genin C, Verrier B, Paul S. New insights in mucosal vaccine development. Vaccine. 2012;30(2):142–54.
211. Johansson E-L, Wassén L, Holmgren J, Jertborn M, Rudin A. Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans. Infect Immun. 2001;69(12):7481–6.
212. Lowry D. Vaginal delivery of subunit vaccines. In: Foged C, Rades T, Perrie Y, Hook S, editors. Subunit vaccine delivery. Advances in delivery science and technology. New York: Springer; 2015. p. 331–46.
213. Jain S, Khomane K, Jain AK, Dani P. Nanocarriers for transmucosal vaccine delivery. Curr Nanosci. 2011;7(2):160–77.
214. Gherardi MM, Pérez-Jiménez E, Nájera JL, Esteban M. Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule. J Immunol. 2004;172(10):6209–20.
215. Lee M-Y, Shin M-C, Yang VC. Transcutaneous antigen delivery system. BMB Rep. 2013;46(1):17–24.
216. Seneschal J, Clark RA, Gehad A, Baecher-Allan CM, Kupper TS. Human epidermal langerhans cells maintain immune homeostasis in skin by activating skin resident regulatory T cells. Immunity. 2012;36(5):873–84.
217. Kaplan DH. In vivo function of langerhans cells and dermal DC. Trends Immunol. 2010;31(12):446–51.
218. Rattanapak T, Foged C, Hook S. Transcutaneous Immunization. In: Foged C, Rades T, Perrie Y, Hook S, editors. Subunit Vaccine Delivery. Advances in Delivery Science and Technology. New York: Springer; 2015. p. 347–69.
219. Araki S, Wakabayashi R, Moniruzzaman M, Kamiya N, Goto M. Ionic liquid-mediated transcutaneous protein delivery with solid-in-oil nanodispersions. Med Chem Commun. 2015;6(12):2124–8.
220. El Maghraby GM, Barry BW, Williams AC. Liposomes and skin: from drug delivery to model membranes. Eur J Pharm Sci. 2008;34(4–5):203–22.
221. Cevc G, Schätzlein A, Richardsen H. Ultradeformable lipid vesicles can penetrate the skin and other semi-permeable barriers unfragmented. Evidence from double label CLSM experiments and direct size measurements. Biochim Biophys Acta Biomembr. 2002;1564(1):21–30.
222. Touitou E, Dayan N, Bergelson L, Godin B, Eliaz M. Ethosomes — novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. J Control Release. 2000;65(3):403–18.
223. Li N, Peng L-H, Chen X, Nakagawa S, Gao J-Q. Effective transcutaneous immunization by antigen-loaded flexible liposome in vivo. Int J Nanomedicine. 2011;6:3241–50.
224. Hansen S, Lehr C-M. Nanoparticles for transcutaneous vaccination. Microb Biotechnol. 2012;5(2):156–67.
225. Rattanapak T, Young K, Rades T, Hook S. Comparative study of liposomes, transfersomes, ethosomes and cubosomes for transcutaneous immunisation: characterisation and in vitro skin penetration. J Pharm Pharmacol. 2012;64(11):1560–9.
226. Li N, Peng L-H, Chen X, Zhang T-Y, Shao G-F, Liang W-Q, et al. Antigen-loaded nanocarriers enhance the migration of stimulated Langerhans cells to draining lymph nodes and induce effective transcutaneous immunization. Nanomed: Nanotechnol Biol Med. 2014;10(1):215–23.
227. Bronaugh RL, Stewart RF, Congdon ER. Methods for in vitro percutaneous absorption studies II. Animal models for human skin. Toxicol Appl Pharmacol. 1982;62(3):481–8.
228. Hirobe S, Okada N, Nakagawa S. Transcutaneous vaccines – current and emerging strategies. Expert Opin Drug Deliv. 2013;10(4):485–98.
229. Dahlan A, Alpar HO, Stickings P, Sesardic D, Murdan S. Transcutaneous immunisation assisted by low-frequency ultrasound. Int J Pharm. 2009;368(1–2):123–8.
230. Zhao YL, Murthy SN, Manjili MH, Guan LJ, Sen A, Hui SW. Induction of cytotoxic T-lymphocytes by electroporation-enhanced needle-free skin immunization. Vaccine. 2006;24(9):1282–90.
231. Chen D, Weis KF, Chu Q, Erickson C, Endres R, Lively CR, et al. Epidermal powder immunization induces both cytotoxic T-lymphocyte and antibody responses to protein antigens of influenza and hepatitis B viruses. J Virol. 2001;75(23):11630–40.
232. Cassaday RD, Sondel PM, King DM, Macklin MD, Gan J, Warner TF, et al. A phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients. Clin Cancer Res. 2007;13(2):540–9.
233. Engelke L, Winter G, Hook S, Engert J. Recent insights into cutaneous immunization: how to vaccinate via the skin. Vaccine. 2015;33(37):4663–74.
234. Terhorst D, Fossum E, Baranska A, Tamoutounour S, Malosse C, Garbani M, et al. Laser-assisted intradermal delivery of adjuvant-free vaccines targeting XCR1+ dendritic cells induces potent antitumoral responses. J Immunol. 2015;194(12):5895–902.
235. Kim Y-C, Park J-H, Prausnitz MR. Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev. 2012;64(14):1547–68.
236. Burton S, Ng C-Y, Simmers R, Moeckly C, Brandwein D, Gilbert T, et al. Rapid intradermal delivery of liquid formulations using a hollow microstructured array. Pharm Res. 2011;28(1):31–40.
237. Martin CJ, Allender CJ, Brain KR, Morrissey A, Birchall JC. Low temperature fabrication of biodegradable sugar glass microneedles for transdermal drug delivery applications. J Control Release. 2012;158(1):93–101.
238. DeMuth PC, Min Y, Irvine DJ, Hammond PT. Implantable silk composite microneedles for programmable vaccine release kinetics and enhanced immunogenicity in transcutaneous immunization. Adv Healthc Mater. 2014;3(1):47–58.
239. Rattanapak T, Birchall J, Young K, Ishii M, Meglinski I, Rades T, et al. Transcutaneous immunization using microneedles and cubosomes: mechanistic investigations using optical coherence tomography and two-photon microscopy. J Control Release. 2013;172(3):894–903.
240. Hirobe S, Azukizawa H, Hanafusa T, Matsuo K, Quan Y-S, Kamiyama F, et al. Clinical study and stability assessment of a novel transcutaneous influenza vaccination using a dissolving microneedle patch. Biomaterials. 2015;57:50–8.